Nuveen
EDIT icon

Nuveen’s Editas Medicine EDIT Stock Holding History

Nuveen’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Sell
521,213
-1,456,296
-74% -$4.26M ﹤0.01% 2666
2026
Q1 		$4.88M Buy
1,977,509
+609
+0% +$1.29K ﹤0.01% 1893
2025
Q4 		$4.05M Sell
1,976,900
-114,736
-5% -$331K ﹤0.01% 2002
2025
Q3 		$7.26M Buy
2,091,636
+1,141,792
+120% +$3.19M ﹤0.01% 1728
2025
Q2 		$2.09M Buy
949,844
+633,230
+200% +$1.04M ﹤0.01% 2283
2025
Q1 		$367K Hold
316,614
– – ﹤0.01% 2991
2024
Q4 		$402K Buy
316,614
+60,583
+24% +$154K ﹤0.01% 3052
2024
Q3 		$873K Hold
256,031
– – ﹤0.01% 2818
2024
Q2 		$1.2M Sell
256,031
-767,149
-75% -$4.33M ﹤0.01% 2644
2024
Q1 		$7.59M Buy
1,023,180
+377,377
+58% +$3.14M ﹤0.01% 1764
2023
Q4 		$6.54M Sell
645,803
-303,312
-32% -$2.66M ﹤0.01% 1823
2023
Q3 		$7.4M Buy
949,115
+263,458
+38% +$2.26M ﹤0.01% 1653
2023
Q2 		$5.64M Buy
685,657
+202,691
+42% +$1.77M ﹤0.01% 1847
2023
Q1 		$3.5M Sell
482,966
-207,325
-30% -$1.84M ﹤0.01% 2083
2022
Q4 		$6.12M Buy
690,291
+106,544
+18% +$1.17M ﹤0.01% 1802
2022
Q3 		$7.15M Sell
583,747
-2,153
-0.4% -$33.5K ﹤0.01% 1689
2022
Q2 		$6.93M Sell
585,900
-9,065
-2% -$121K ﹤0.01% 1744
2022
Q1 		$10.4M Buy
594,965
+36,522
+7% +$679K ﹤0.01% 1622
2021
Q4 		$16M Sell
558,443
-66,198
-11% -$2.28M ﹤0.01% 1369
2021
Q3 		$39.5M Buy
624,641
+24,149
+4% +$1.32M 0.01% 819
2021
Q2 		$34M Buy
600,492
+114,155
+23% +$4.22M 0.01% 981
2021
Q1 		$20.4M Buy
486,337
+15,104
+3% +$860K 0.01% 1308
2020
Q4 		$33M Buy
471,233
+1,833
+0.4% +$75.3K 0.01% 924
2020
Q3 		$13.2M Buy
469,400
+172,940
+58% +$5.63M 0.01% 1336
2020
Q2 		$8.77M Sell
296,460
-32,292
-10% -$844K ﹤0.01% 1566
2020
Q1 		$6.52M Buy
328,752
+73,787
+29% +$1.86M ﹤0.01% 1557
2019
Q4 		$7.55M Buy
254,965
+46,171
+22% +$1.15M ﹤0.01% 1753
2019
Q3 		$4.75M Buy
208,794
+25,097
+14% +$622K ﹤0.01% 1984
2019
Q2 		$4.54M Buy
+183,697
New +$4.38M ﹤0.01% 2045

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Nuveen's EDIT Position: Q2 2026 in Review

Nuveen reduced its Editas Medicine (EDIT) stake by 74% in Q2 2026, selling an estimated $4.26M and leaving 521,213 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2666.

Nuveen first reported a position in EDIT in Q2 2019 and has held it in 29 quarters since. The position peaked at $39.5M in Q3 2021. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Nuveen held 521,213 shares of Editas Medicine worth $1.69M as of Q2 2026.
  • Nuveen sold 1,456,296 Editas Medicine shares in Q2 2026, an estimated $4.26M.
  • Editas Medicine made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2666 holding.
  • Nuveen first reported a position in Editas Medicine in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Editas Medicine position peaked at $39.5M in Q3 2021.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.